A Case Report of End-of-Dosage Failure With Buprenorphine Patch

Key Points

• End-of-dosage failure was observed with the buprenorphine patch, negatively affecting pain relief.
• Key evidence indicates significant pain resurgence after patch effectiveness diminished over time.
• Reporting a case of dosage failure, the evaluation involved clinical assessments over several weeks.
• The report highlights the need for careful monitoring of patients on transdermal opioid therapy.